• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    G1 Therapeutics, Inc. - Common Stock (NQ: GTHX )

    7.150 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about G1 Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
    From G1 Therapeutics
    Via GlobeNewswire
    Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
    From G1 Therapeutics
    Via GlobeNewswire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
    G1 Therapeutics stock is up on Wednesday following news that Pharmacosmos Group is acquiring GTHX for $7.15 per share. 
    Via InvestorPlace
    Analyst Ratings For G1 Therapeutics
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX
    From Kahn Swick & Foti, LLC
    Via Business Wire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
    From G1 Therapeutics
    Via GlobeNewswire
    Dow Tumbles Over 200 Points; CVS Health Cuts Profit Forecast
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Crude Oil Jumps Over 3%; Upstart Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    Nasdaq Jumps 250 Points; Disney Earnings Beat Estimates
    Via Benzinga
    Topics Earnings
    Exposures Financial
    GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning! 
    Via InvestorPlace
    Pharmacosmos Group to Acquire G1 Therapeutics
    From G1 Therapeutics; Pharmacosmos
    Via GlobeNewswire
    G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
    From G1 Therapeutics
    Via GlobeNewswire
    G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
    While there’s no denying that G1 Therapeutics stock is highly speculative, investors should still check under the hood. 
    Via InvestorPlace
    Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
    G1 Therapeutics stock is highly volatile, and investors should be wary now as G1 Therapeutics recently failed to achieve a clinical goal. 
    Via InvestorPlace
    Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
    A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees. 
    Via InvestorPlace
    Exposures Product Safety
    Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
    Ginkgo Bioworks layoffs are a hot topic as the company prepares to cut 158 jobs this week with more headcount reductions coming next week. 
    Via InvestorPlace
    Topics Workforce
    Exposures Layoff
    Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
    Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and... 
    Via Benzinga
    Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
    Shares of G1 Therapeutics are down after release of Phase 3 trial results for trilaciclib in TNBC. 
    Via Benzinga
    Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
    G1 Therapeutics stock is down on Monday as GTHX investors react to the company's Phase 3 clinical trial of trilaciclib failing. 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news on Monday morning! 
    Via InvestorPlace
    G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
    From G1 Therapeutics
    Via GlobeNewswire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.